Alongside the launch, Clinigen KK will transfer the Marketing Authorisation for its lead Specialty Pharmaceutical product, Foscavir
(foscarnet sodium), back from Nobel Pharma on 1 November 2016.
In October the company received a top US award for making a pioneering new drug - Foscavir
- more widely available.
The deal comes after Clinigen gaining the anti-viral Foscavir
from AstraZeneca in 2010.
Currently, only two drugs, Cytovene and Foscavir
, are commonly used for treatment of HHV-6.
Immunosuppressive therapy was stopped, and Foscavir
(6 g/d) and intravenous immunoglobulins (total dose 2 g/ kg) were added to the broad spectrum antimicrobial drugs given since admission.
Foscarnet sodium injection, 24 mg/ Foscavir
Approved February 1997 for combination therapy with foscavir
and ganciclovir of patients who have relapsed after monotherapy with either drug.
Hospira granted exclusive rights to market, promote and distribute Foscavir
in the US
M2 EQUITYBITES-May 8, 2012-Clinigen wins US FDA approval for Foscavir
in HIV/AIDS-related cytomegalovirus infections and herpes(C)2012 M2 COMMUNICATIONS http://www.
50] Virus Foscavir
50-800 [micro]mol/L Cytomegalovirus 5-443 [micro]mol/L Herpes simplex mutants Acyclovir 0.
(foscarnet) for the treatment of AIDS patients who suffer from cytomegalovirus (CMV) retinitis.
Clinigen Healthcare acquired Foscavir
(foscarnet sodium) from AstraZeneca in 2010, seeing sales grow six-fold in 2011.